With a maze of regulations across global jurisdictions and even more complex, temperature-sensitive pharmaceutical and healthcare product requirements, the life sciences supply chain is under pressure to adapt. And from the EU’s Good Distribution Practice guidelines to Brazil’s stringent serialization laws, regulatory compliance is only increasing. In the U.S., serialization, the next phase of the Drug Supply Chain Security Act (DSCSA), goes into effect next year for pharmaceutical manufacturers. By 2023, the Act will ensure that manufacturers, repackagers, distributors and dispensers can only transact with serialized product, ensuring unit level traceability across the pharma supply chain. How are supply chain leaders in the pharmaceutical and healthcare industries coping?